Kairos Pharma, Ltd.
KAPAAMEXHealthcareBiotechnology
Previous close
$0.29
−$0.0051 · -1.73%
KAPA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
17
Strong Down
Sentiment
54
Mixed
Risk resilience
21
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteKairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- John S. Yu
- Listed since
- Sep 16, 2024
- Employees
- 4
Market position
Day range
Current $0.29
52-week range
Current $0.29
- Open
- $0.2963
- Previous close
- $0.2951
- Volume
- 110.56K
- 0.06× average
- Average volume
- 1.96M
- Average daily volume
- Market cap
- 6.21M USD
- Beta
- 1.56
- Market reference 1
- 50-day average
- $0.3554
- -18.40% below average
- 200-day average
- $0.5861
- -50.52% below average
Financials
Financial snapshot
Latest / TTMFinancial health
- Altman Z-score
- 5.11
- Piotroski F-score
- 2 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 160K USD | 160K USD | 160K USD | 98K USD |
| Gross profit | — | −160K USD | −160K USD | −160K USD | −98K USD |
| Research and development | 2.14M USD | 414K USD | 82K USD | 87K USD | 183K USD |
| Selling, general, and administrative | 3.44M USD | 1.77M USD | 1.47M USD | 324K USD | 1.66M USD |
| Operating expenses | 5.57M USD | 2.18M USD | 1.55M USD | 411K USD | 1.85M USD |
| Interest income | 125K USD | — | — | — | — |
| Interest expense | — | 859K USD | 98K USD | 479K USD | 202K USD |
| Depreciation and amortization | 160K USD | 160K USD | 160K USD | 160K USD | 98K USD |
| Operating income | −5.57M USD | −2.34M USD | −1.71M USD | −571K USD | −1.94M USD |
| Net income | −5.45M USD | −2.6M USD | −1.81M USD | −1.05M USD | −2.15M USD |
Company facts updated Aug 24, 2026.
Earnings
- Latest fiscal-year EPS
- -0.3
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
- Next fiscal-year EPS consensus
- -0.555
- FY2028 · 2 analysts
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
KAPA peers
Continue in GoAI
Research KAPAresearch.disclaimer